Global Cancer Biomarkers Market Overview

The Cancer Biomarkers Market size is anticipated to reach USD 48.52 billion by 2028 from an estimated USD 16.56 billion in 2021, growing at a CAGR of 16.6% globally.

The biomarkers are also referred to as molecular markers of the signature molecule. The National Cancer Institute (NCI) states that a biomarker is a biological molecule that is found in body tissues, blood, and other body fluids that is a sign of any abnormal or normal process or any disease and other conditions. It can be RNA, DNA, protein, or metabolomic profiles which are specific to the tumor. The various type of cancer biomarkers based on the cancer type includes ER/PR, HER-2/neu, EGFR, and KRAS. The first cancer biomarker was discovered in 1847 and the name of that biomarker was the Bence-Jones protein. Biomarkers check out the individual’s risk of developing cancer and determine the risk of recurrence of cancer. This also helps doctors of the patients in choosing cancer treatment. Biomarkers are used to find how well patients’ body responds to the treatment of diseases. The growing prevalence of cancer rises the demand for biomarkers that provide growth to the market.

Market Dynamics And Factors For Cancer Biomarkers Market

Drivers:

Growing Prevalence of The Cancer

In the past few decays, the rise in the prevalence of the various types of cancer is expected to witness significant growth in the cancer biomarkers market. According to the report of the World Cancer Research Fund International in 2020, there were 18.1 million cases in the world.

Statista stated that there were 10 million deaths caused by cancer in the world in the same year. The following figure shows the top five types of cancer which have the maximum number of patients in the year 2020.

Owing changing habits and lifestyles of people that which responsible for the increasing number of cancer patients. For instance, smoking, consumption of alcohol, poor diet, and use of chemicals for cosmetic purposes like hair dyes. These are the main causes of cancer. Statista states that around 280 billion liters of alcoholic beverages consumed in the world in 2021. Thus, the growing incidence of cancer which propels the growth of the cancer biomarkers market.

Restraints:

Shortage Of Reimbursement Policies       

The lack of reimbursement regulations for biomarker tests is a key factor that hampers the growth of the cancer biomarkers market. The government of various developing, as well as underdeveloped countries, does not offer favorable reimbursement policies. The reimbursement policy requirement is rising due to the growing number of cancer patients. Apart from this lack of resources for the research and development of the biomarkers. Also, insufficiency of finance for the development of the biomarkers of the developing and under-developing countries. These factors restrict the growth of the cancer biomarkers market.

Opportunities

Opportunity in The Growing technological developments

Advanced technology helps to develop cancer biomarkers with new advanced features that offer a lucrative opportunity for the cancer biomarkers market. Healthcare research centers increasing their investment in digital biomarkers. These digital biomarkers are generated from different sources such as body sensors, image processing, or from health platforms, and electronic medical records. Digital biomarkers provide more accurate diagnostic and prognostic markers for cancer patients. Thus, the rising impact of digital biomarkers on patient care or cancer research. Moreover, novel technology, devices, and gadgets are developed to address new problems of cancer that provide the remunerative opportunity for the cancer biomarkers market during the forecast periods.

Segmentation Analysis Of Cancer Biomarkers Market

By Biomarker Type, protein biomarker is expected to account for the largest market share in the forecasted period. The protein biomarker is used for the early detection of the breast as well as colonic cancer. Breast cancer and colon cancer are the most common type of cancer and major cause of death around the world. According to WHO, around 2.3 million women were diagnosed with breast cancer and 685,000 death occurred due to breast cancer in 2020 worldwide and 1.9 million people were colonic cancer. The growing cases of breast cancer as well as colon cancer, increase the R&D of the protein biomarkers. For instance, the Food and Drug Administration (FDA) approved the protein biomarkers which contain carcinoembryonic antigen (CEA) in colon cancer, cancer antigen 125 (CA125) in ovarian cancer, and prostate-specific antigen (PSA) in prostate cancer.  Thus, the protein biomarkers have maximum growth in the cancer biomarkers market.

By Cancer Type, breast cancer is projected to have the maximum market share in the cancer biomarker market during the analysis period. Breast cancer is one of the most common cancers in women. Breast cancer occurs due to various reasons such as genetic mutation, being overweight, reproductive history, and alcohol drinking.  The risk of breast cancer increases the age. In 2020, there were 55% of women aged 65 years old or over. Protein biomarkers are the choice for the treatment of breast cancer. Thus, the growing incidence of breast cancer among women which is the rising demand for biomarkers for treatment propels the growth of the cancer biomarkers market.

By End-Users, the Academic & Cancer Research Institutes are expected to have the highest market share in cancer biomarkers during the projected timeframe. Owing to the growing prevalence of cancer, rising research and development of advanced treatments. Additionally, a rising number of research centers in the world. The government of various countries increases their investment in research centers. Thus, the biomarkers are mostly adopted in academic & cancer research institutes that provide growth to the market.

Regional Analysis Of Cancer Biomarkers Market

North America is the dominant region in the cancer biomarkers market owing to the growing number of cancer patients. The increasing number of tobacco, and alcohol consumption, unhealthy food habits, genetic mutation, hormonal imbalance, growing demand for early diagnosis, and the rising geriatric population in this region. These are the common causes of cancer. For instance, there were 32.51 million Americans smoked cigarettes in the year 2020. Statista stated that in 2020 North America had the highest 12-month rate of the prevalence of cancer. Thus, the incidence of cancer in this region is increased. In the United State, there were236 thousand lung cancer cases diagnosed in 2021. Growing awareness about the treatment of cancer among American people the organizations increasing their investment in research and development of biomarkers for cancer treatment. Growing population with cancer and rising investment in the development of biomarkers people the growth of the cancer biomarkers market in the North American region.

The Asia Pacific is the second-dominated region in the cancer biomarker market. This is due to the growing prevalence of the different types of cancer. After the United States, China and India have the highest number of blood cancer patients. According to Globocan 2020, there were over 20,000 children with blood cancer are diagnosed every year in India. In China, lung cancer is the most common type. For instance, Statista stated that over 800 thousand incidences of lung cancer in China and more than 4.5 million cancer cases in this country in 2020. The incidence of cancer is increased due to unhealthy lifestyles and habits of the people. As per the WHO report, the production and consumption of tobacco are the largest occurs in China.  There are over 300 smokers in China. Thus, most cancer patients are seen in China and India. Moreover, in the APAC region, the highest number of healthcare sectors are present and growing prevalence of cancer in this region they increasing their investment in the research and development of new biomarkers for the treatment of cancer. Henceforth, the market of cancer biomarkers in the APAC region is expected to grow during the forecast year.

Europe has significant growth in the cancer biomarkers market owing to the high adoption of advanced technology and a growing number of cancer patients. For instance, according to Globocan 2020 report in the United Kingdom, there were 457,960 cases which prostate, lung, breast, skin, and colon cancer are the most commonly detected in the UK, and in Italy, there were 415,269 cancerous cases. This growing incidence is due to the rising unhealthy habits among the European people. The following figure shows the percentage of people who smoke cigarettes in European countries in 2020.

Thus, for the treatment of the cancer the European healthcare sectors and government rising their investment in the research and development of biomarkers. Lung cancer biomarker testing is performed in several European countries.

Covid-19 Impact Analysis On Cancer Biomarkers Market

COVID-19 began in Wuhan (China) in December 2019 and has since rapidly grown around the globe. In terms of confirmed cases and reported deaths, the US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are among the countries that have been most severely impacted. Because of the lockdowns, travel restrictions, and business closures, COVID-19 has had an impact on the businesses and industries of numerous nations. The covid-19 has had a positive impact on the healthcare system. During the pandemic, the pharmaceutical industries engaged in research and development activity. Thus, growing demand for cancer biomarkers in the healthcare sectors. Cancer patients are more susceptible to Covid-19, thus increasing the risk of severe health complications. People with metastatic and hematological cancer are more affected by severe Covid-19.  The biomarkers like interleukin-6 and C-reactive protein were used for the treatment. Henceforth, COVID-19 has had a positive impact on the cancer biomarkers market.

Top Key Players Covered In Cancer Biomarkers Market

• BioMérieux Inc. (France)
• INOVIQ (Australia)
• Bio-Rad Laboratories Inc. (California)
• Abbott(US)
• Becton, Dickinson, and Company (US)
• Merck KgaA (Germany)
• QIAGEN (Germany)
• Thermo Fisher Scientific Inc. (US)
• CENTOGENE N.V. (Germany)
• PerkinElmer Inc. (US)
• Siemens Healthcare Private Limited (Germany), and other major players.

Key Industry Development In The Cancer Biomarkers Market

In April 2021, F. Hoffmann-La Roche Ltd. (Switzerland), established Elecsys Anti-p53 immunoassay for the diagnosis of various cancer types.

In December 2020, FDA approves the NGS-based companion diagnostic of Thermo Fisher Scientific (US) for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Cancer Biomarkers Market by Type
 5.1 Cancer Biomarkers Market Overview Snapshot and Growth Engine
 5.2 Cancer Biomarkers Market Overview
 5.3 Neurostimulation
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Neurostimulation: Geographic Segmentation
 5.4 Imaging Modalities
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Imaging Modalities: Geographic Segmentation
 5.5 Neurological Implants
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Neurological Implants: Geographic Segmentation
 5.6 Cranial Surface Measurement
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Cranial Surface Measurement: Geographic Segmentation
 5.7 Others
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size (2016-2028F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Others: Geographic Segmentation

Chapter 6: Cancer Biomarkers Market by Application
 6.1 Cancer Biomarkers Market Overview Snapshot and Growth Engine
 6.2 Cancer Biomarkers Market Overview
 6.3 Diagnostic Centers
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Diagnostic Centers: Geographic Segmentation
 6.4 Ambulatory Surgical Centers
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Ambulatory Surgical Centers: Geographic Segmentation
 6.5 Hospitals
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Hospitals: Geographic Segmentation
 6.6 Clinics
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Clinics: Geographic Segmentation
 6.7 Others
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2016-2028F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Others: Geographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Cancer Biomarkers Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Cancer Biomarkers Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Cancer Biomarkers Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 BIOMÉRIEUX INC.
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 INOVIQ
 7.4 BIO-RAD LABORATORIES
 7.5 INC.
 7.6 ABBOTT
 7.7 BECTON
 7.8 DICKINSON & COMPANY
 7.9 MERCK KGAA
 7.10 QIAGEN
 7.11 THERMO FISHER SCIENTIFIC INC.
 7.12 CENTOGENE N.V.
 7.13 PERKINELMER INC.
 7.14 SIEMENS HEALTHCARE PRIVATE LIMITED
 7.15 OTHER MAJOR PLAYERS

Chapter 8: Global Cancer Biomarkers Market Analysis, Insights and Forecast, 2016-2028
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Type
  8.2.1 Neurostimulation
  8.2.2 Imaging Modalities
  8.2.3 Neurological Implants
  8.2.4 Cranial Surface Measurement
  8.2.5 Others
 8.3 Historic and Forecasted Market Size By Application
  8.3.1 Diagnostic Centers
  8.3.2 Ambulatory Surgical Centers
  8.3.3 Hospitals
  8.3.4 Clinics
  8.3.5 Others

Chapter 9: North America Cancer Biomarkers Market Analysis, Insights and Forecast, 2016-2028
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Type
  9.4.1 Neurostimulation
  9.4.2 Imaging Modalities
  9.4.3 Neurological Implants
  9.4.4 Cranial Surface Measurement
  9.4.5 Others
 9.5 Historic and Forecasted Market Size By Application
  9.5.1 Diagnostic Centers
  9.5.2 Ambulatory Surgical Centers
  9.5.3 Hospitals
  9.5.4 Clinics
  9.5.5 Others
 9.6 Historic and Forecast Market Size by Country
  9.6.1 U.S.
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Europe Cancer Biomarkers Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Type
  10.4.1 Neurostimulation
  10.4.2 Imaging Modalities
  10.4.3 Neurological Implants
  10.4.4 Cranial Surface Measurement
  10.4.5 Others
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Diagnostic Centers
  10.5.2 Ambulatory Surgical Centers
  10.5.3 Hospitals
  10.5.4 Clinics
  10.5.5 Others
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Germany
  10.6.2 U.K.
  10.6.3 France
  10.6.4 Italy
  10.6.5 Russia
  10.6.6 Spain
  10.6.7 Rest of Europe

Chapter 11: Asia-Pacific Cancer Biomarkers Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 Neurostimulation
  11.4.2 Imaging Modalities
  11.4.3 Neurological Implants
  11.4.4 Cranial Surface Measurement
  11.4.5 Others
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Diagnostic Centers
  11.5.2 Ambulatory Surgical Centers
  11.5.3 Hospitals
  11.5.4 Clinics
  11.5.5 Others
 11.6 Historic and Forecast Market Size by Country
  11.6.1 China
  11.6.2 India
  11.6.3 Japan
  11.6.4 Singapore
  11.6.5 Australia
  11.6.6 New Zealand
  11.6.7 Rest of APAC

Chapter 12: Middle East & Africa Cancer Biomarkers Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 Neurostimulation
  12.4.2 Imaging Modalities
  12.4.3 Neurological Implants
  12.4.4 Cranial Surface Measurement
  12.4.5 Others
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Diagnostic Centers
  12.5.2 Ambulatory Surgical Centers
  12.5.3 Hospitals
  12.5.4 Clinics
  12.5.5 Others
 12.6 Historic and Forecast Market Size by Country
  12.6.1 Turkey
  12.6.2 Saudi Arabia
  12.6.3 Iran
  12.6.4 UAE
  12.6.5 Africa
  12.6.6 Rest of MEA

Chapter 13: South America Cancer Biomarkers Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Type
  13.4.1 Neurostimulation
  13.4.2 Imaging Modalities
  13.4.3 Neurological Implants
  13.4.4 Cranial Surface Measurement
  13.4.5 Others
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Diagnostic Centers
  13.5.2 Ambulatory Surgical Centers
  13.5.3 Hospitals
  13.5.4 Clinics
  13.5.5 Others
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Brazil
  13.6.2 Argentina
  13.6.3 Rest of SA

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. CANCER BIOMARKERS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. CANCER BIOMARKERS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. CANCER BIOMARKERS MARKET COMPETITIVE RIVALRY
TABLE 005. CANCER BIOMARKERS MARKET THREAT OF NEW ENTRANTS
TABLE 006. CANCER BIOMARKERS MARKET THREAT OF SUBSTITUTES
TABLE 007. CANCER BIOMARKERS MARKET BY TYPE
TABLE 008. NEUROSTIMULATION MARKET OVERVIEW (2016-2028)
TABLE 009. IMAGING MODALITIES MARKET OVERVIEW (2016-2028)
TABLE 010. NEUROLOGICAL IMPLANTS MARKET OVERVIEW (2016-2028)
TABLE 011. CRANIAL SURFACE MEASUREMENT MARKET OVERVIEW (2016-2028)
TABLE 012. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 013. CANCER BIOMARKERS MARKET BY APPLICATION
TABLE 014. DIAGNOSTIC CENTERS MARKET OVERVIEW (2016-2028)
TABLE 015. AMBULATORY SURGICAL CENTERS MARKET OVERVIEW (2016-2028)
TABLE 016. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 017. CLINICS MARKET OVERVIEW (2016-2028)
TABLE 018. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 019. NORTH AMERICA CANCER BIOMARKERS MARKET, BY TYPE (2016-2028)
TABLE 020. NORTH AMERICA CANCER BIOMARKERS MARKET, BY APPLICATION (2016-2028)
TABLE 021. N CANCER BIOMARKERS MARKET, BY COUNTRY (2016-2028)
TABLE 022. EUROPE CANCER BIOMARKERS MARKET, BY TYPE (2016-2028)
TABLE 023. EUROPE CANCER BIOMARKERS MARKET, BY APPLICATION (2016-2028)
TABLE 024. CANCER BIOMARKERS MARKET, BY COUNTRY (2016-2028)
TABLE 025. ASIA PACIFIC CANCER BIOMARKERS MARKET, BY TYPE (2016-2028)
TABLE 026. ASIA PACIFIC CANCER BIOMARKERS MARKET, BY APPLICATION (2016-2028)
TABLE 027. CANCER BIOMARKERS MARKET, BY COUNTRY (2016-2028)
TABLE 028. MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET, BY TYPE (2016-2028)
TABLE 029. MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET, BY APPLICATION (2016-2028)
TABLE 030. CANCER BIOMARKERS MARKET, BY COUNTRY (2016-2028)
TABLE 031. SOUTH AMERICA CANCER BIOMARKERS MARKET, BY TYPE (2016-2028)
TABLE 032. SOUTH AMERICA CANCER BIOMARKERS MARKET, BY APPLICATION (2016-2028)
TABLE 033. CANCER BIOMARKERS MARKET, BY COUNTRY (2016-2028)
TABLE 034. BIOMÉRIEUX INC.: SNAPSHOT
TABLE 035. BIOMÉRIEUX INC.: BUSINESS PERFORMANCE
TABLE 036. BIOMÉRIEUX INC.: PRODUCT PORTFOLIO
TABLE 037. BIOMÉRIEUX INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 037. INOVIQ: SNAPSHOT
TABLE 038. INOVIQ: BUSINESS PERFORMANCE
TABLE 039. INOVIQ: PRODUCT PORTFOLIO
TABLE 040. INOVIQ: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 040. BIO-RAD LABORATORIES: SNAPSHOT
TABLE 041. BIO-RAD LABORATORIES: BUSINESS PERFORMANCE
TABLE 042. BIO-RAD LABORATORIES: PRODUCT PORTFOLIO
TABLE 043. BIO-RAD LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. INC.: SNAPSHOT
TABLE 044. INC.: BUSINESS PERFORMANCE
TABLE 045. INC.: PRODUCT PORTFOLIO
TABLE 046. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. ABBOTT: SNAPSHOT
TABLE 047. ABBOTT: BUSINESS PERFORMANCE
TABLE 048. ABBOTT: PRODUCT PORTFOLIO
TABLE 049. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. BECTON: SNAPSHOT
TABLE 050. BECTON: BUSINESS PERFORMANCE
TABLE 051. BECTON: PRODUCT PORTFOLIO
TABLE 052. BECTON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. DICKINSON & COMPANY: SNAPSHOT
TABLE 053. DICKINSON & COMPANY: BUSINESS PERFORMANCE
TABLE 054. DICKINSON & COMPANY: PRODUCT PORTFOLIO
TABLE 055. DICKINSON & COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. MERCK KGAA: SNAPSHOT
TABLE 056. MERCK KGAA: BUSINESS PERFORMANCE
TABLE 057. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 058. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. QIAGEN: SNAPSHOT
TABLE 059. QIAGEN: BUSINESS PERFORMANCE
TABLE 060. QIAGEN: PRODUCT PORTFOLIO
TABLE 061. QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. THERMO FISHER SCIENTIFIC INC.: SNAPSHOT
TABLE 062. THERMO FISHER SCIENTIFIC INC.: BUSINESS PERFORMANCE
TABLE 063. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 064. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. CENTOGENE N.V.: SNAPSHOT
TABLE 065. CENTOGENE N.V.: BUSINESS PERFORMANCE
TABLE 066. CENTOGENE N.V.: PRODUCT PORTFOLIO
TABLE 067. CENTOGENE N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. PERKINELMER INC.: SNAPSHOT
TABLE 068. PERKINELMER INC.: BUSINESS PERFORMANCE
TABLE 069. PERKINELMER INC.: PRODUCT PORTFOLIO
TABLE 070. PERKINELMER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. SIEMENS HEALTHCARE PRIVATE LIMITED: SNAPSHOT
TABLE 071. SIEMENS HEALTHCARE PRIVATE LIMITED: BUSINESS PERFORMANCE
TABLE 072. SIEMENS HEALTHCARE PRIVATE LIMITED: PRODUCT PORTFOLIO
TABLE 073. SIEMENS HEALTHCARE PRIVATE LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 074. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 075. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 076. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. CANCER BIOMARKERS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. CANCER BIOMARKERS MARKET OVERVIEW BY TYPE
FIGURE 012. NEUROSTIMULATION MARKET OVERVIEW (2016-2028)
FIGURE 013. IMAGING MODALITIES MARKET OVERVIEW (2016-2028)
FIGURE 014. NEUROLOGICAL IMPLANTS MARKET OVERVIEW (2016-2028)
FIGURE 015. CRANIAL SURFACE MEASUREMENT MARKET OVERVIEW (2016-2028)
FIGURE 016. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 017. CANCER BIOMARKERS MARKET OVERVIEW BY APPLICATION
FIGURE 018. DIAGNOSTIC CENTERS MARKET OVERVIEW (2016-2028)
FIGURE 019. AMBULATORY SURGICAL CENTERS MARKET OVERVIEW (2016-2028)
FIGURE 020. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 021. CLINICS MARKET OVERVIEW (2016-2028)
FIGURE 022. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 023. NORTH AMERICA CANCER BIOMARKERS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 024. EUROPE CANCER BIOMARKERS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. ASIA PACIFIC CANCER BIOMARKERS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. SOUTH AMERICA CANCER BIOMARKERS MARKET OVERVIEW BY COUNTRY (2016-2028)